Skip to main content
. 2020 Sep 1;24(20):11984–11997. doi: 10.1111/jcmm.15823

Figure 7.

Figure 7

Effect of CGRP receptor antagonist CGRP8‐37 on growth and angiogenesis/lymphangiogenesis in endometrial tissue implants. A, The area of the implants in WT → WT mice treated with continuous administration of CGRP8‐37 or vehicle. Data are expressed as the mean ± SD (n = 6 mice per group). *P < .05. B, MVD, LVD and LVA% in mice treated with continuous administration of CGRP8‐37 or vehicle. Data are expressed as the mean ± SD (n = 4‐6 mice per group). *P < .05. C, Double immunofluorescence staining of CD11b (red) and LYVE‐1 (green) in the endometrial tissue implants from WT → WT mice treated with continuous administration of CGRP8‐37 or vehicle on day 14. Scale bars, 50 μm. D, The level of mRNA expression of pro‐angiogenic genes VEGF‐A, CD31 and VEGFR2; lymphangiogenesis‐related genes VEGF‐C, VEGF‐D, LYVE‐1, VEGFR3 and Prox‐1; and chemokine genes CCL2 and SDF‐1 in mice treated with continuous administration of CGRP8‐37 or vehicle. Data are expressed as the mean ± SD (n = 6 mice per group). *P < .05